KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Depreciation and Depletion (2023 - 2025)

Vir Biotechnology's Depreciation and Depletion history spans 3 years, with the latest figure at $2.8 million for Q4 2025.

  • For Q4 2025, Depreciation and Depletion rose 3.7% year-over-year to $2.8 million; the TTM value through Dec 2025 reached $11.4 million, down 19.72%, while the annual FY2025 figure was $11.4 million, 19.72% down from the prior year.
  • Depreciation and Depletion for Q4 2025 was $2.8 million at Vir Biotechnology, down from $2.9 million in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $5.5 million in Q1 2023 and bottomed at $2.7 million in Q4 2024.
  • The 3-year median for Depreciation and Depletion is $3.6 million (2024), against an average of $3.7 million.
  • The largest annual shift saw Depreciation and Depletion plummeted 37.21% in 2024 before it rose 3.7% in 2025.
  • A 3-year view of Depreciation and Depletion shows it stood at $4.3 million in 2023, then tumbled by 37.21% to $2.7 million in 2024, then grew by 3.7% to $2.8 million in 2025.
  • Per Business Quant, the three most recent readings for VIR's Depreciation and Depletion are $2.8 million (Q4 2025), $2.9 million (Q3 2025), and $2.9 million (Q2 2025).